# Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic Lymphoma

> **NCT00608374** · PHASE3 · COMPLETED · sponsor: **Taunton and Somerset Hospital** · enrollment: 400 (estimated)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** chlorambucil
- **DRUG:** fludarabine phosphate
- **PROCEDURE:** quality-of-life assessment

## Key facts

- **NCT ID:** NCT00608374
- **Lead sponsor:** Taunton and Somerset Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2009-12
- **Final completion:** 2013-01
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2013-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00608374

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00608374, "Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic Lymphoma". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00608374. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*